证券代码：300078 证券简称：思创医惠 公告编号：2025-098 思创医惠科技股份有限公司 2025 年第四次临时股东会决议公告 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2025 年 9 月 8 日（星期一）14:45 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 8 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 8 日 9:15 至 15:00 期间的任意时间。 3、现场会议召开地点：浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室 4、会议召开方式：本次股东会采取现场投票表决和网络投票表决相结合的 方式 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 5、会议召集人：公司董事会 6、会议主持人：公司董事长许益冉先生 7、会议召开的合法、合规性：本次股东会的召集、召开及表决程序符合《中 华人民共和 ...

Market Overview - The Shanghai Composite Index closed at 3813.56 points, with a decline of 1.16% [1] - The total trading volume of A-shares reached 23956.82 billion yuan [1] Technical Analysis - A total of 16 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sichuang Medical (300078) with a distance of -0.91% - Nanmo Biology (688265) with a distance of -0.80% - Shandong Weida (002026) with a distance of -0.75% [1] Individual Stock Performance - Sichuang Medical (300078) saw a decrease of 2.81% with a trading turnover rate of 3.15% [1] - Nanmo Biology (688265) decreased by 0.16% with a turnover rate of 1.39% [1] - Shandong Weida (002026) declined by 2.93% with a turnover rate of 2.90% [1] - Qingda Environmental (688501) dropped by 3.86% with a turnover rate of 1.84% [1] - Pulit (002324) fell by 2.62% with a turnover rate of 2.03% [1] - Other notable declines include: - Meili (000815) down by 4.03% - Hezhong (002383) down by 6.95% [1]

证券代码：300078 证券简称：思创医惠 公告编号：2025-097 公司股东路楠及其一致行动人杭州博泰投资管理有限公司、受让方苍南县工 业建设投资有限公司保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司 关于股东签署《股份转让协议之补充协议书》暨控股股东、实际控制 人拟发生变更的进展公告 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、基本情况概述 思创医惠科技股份有限公司（以下简称"公司""本公司"或"上市公司"） 第一大股东路楠先生与苍南县工业建设投资有限公司（以下简称"苍南建投"） 于 2025 年 4 月 26 日签署了《股份转让协议》，约定路楠先生拟通过协议转让的 方式将其所直接持有的本公司共计 62,739,500 股的股份（占公司总股本的 5.61%）转让给苍南建投（以下简称"本次股份转让"），转让完成后路楠先生 不直接持有本公司股份，通过其一致行动人杭州博泰投资管理有限公司（以下简 称"杭州博泰"）间接持有本公司 6,006,776 股的股份（占公司总股本的 0.54%）。 本次股份转让过户完成后，苍南建投 ...

Company Overview - Sichuang Medical Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on November 21, 2003. The company was listed on April 30, 2010. Its main business focuses on smart hospital solutions, including disease research management solutions, smart medical community solutions, healthcare service operations, and AI services based on big data [1]. Financial Performance - For the first half of 2025, Sichuang Medical achieved operating revenue of 545 million yuan, representing a year-on-year growth of 37.32%. However, the net profit attributable to the parent company was -51.83 million yuan, which is a year-on-year increase of 76.74% in losses [2]. Stock Performance - As of August 28, Sichuang Medical's stock price was 3.60 yuan per share, with a market capitalization of 4.024 billion yuan. The stock has increased by 18.42% year-to-date, but has seen a decline of 9.32% over the past 20 days and 6.98% over the past 60 days [1]. - The stock experienced a net outflow of 8.87 million yuan in principal funds, with significant selling pressure observed [1]. Shareholder Information - As of June 30, the number of shareholders for Sichuang Medical was 65,800, a decrease of 10.81% from the previous period. The average circulating shares per person increased by 12.11% to 16,914 shares [2]. Dividend History - Since its A-share listing, Sichuang Medical has distributed a total of 532 million yuan in dividends, but there have been no dividend distributions in the past three years [3].

Market Overview - The Shanghai Composite Index is at 3884.87 points, above the six-month moving average, with a slight increase of 0.03% [1] - The total trading volume of A-shares today is 21,403.55 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 47 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Haosheng Electronics (12.03%) - Senqilin (4.06%) - Shuguang Co., Ltd. (3.72%) [1] Stock Performance Data - The following stocks have notable performance metrics: - Haosheng Electronics: Today's increase of 14.32%, turnover rate of 7.33%, six-month average price of 21.38 yuan, latest price at 23.95 yuan [1] - Senqilin: Today's increase of 5.90%, turnover rate of 6.52%, six-month average price of 20.00 yuan, latest price at 20.81 yuan [1] - Shuguang Co., Ltd.: Today's increase of 5.15%, turnover rate of 10.89%, six-month average price of 3.74 yuan, latest price at 3.88 yuan [1]

Market Overview - The Shanghai Composite Index closed at 3888.00 points, above the six-month moving average, with a slight increase of 0.11% [1] - The total trading volume of A-shares reached 16993.57 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 46 A-shares have surpassed the six-month moving average today, with notable stocks including Shuguang Co., Zhengdan Co., and Dongbai Group, showing divergence rates of 4.78%, 4.68%, and 2.88% respectively [1] - Stocks with smaller divergence rates that have just crossed the six-month moving average include Jinjiang Hotels, Mingchen Health, and Spring Airlines [1] Top Stocks by Divergence Rate - The top three stocks with the highest divergence rates are: - Shuguang Co. (600303) with a price increase of 6.23%, turnover rate of 9.78%, six-month line at 3.74 yuan, latest price at 3.92 yuan, and a divergence rate of 4.78% [1] - Zhengdan Co. (300641) with a price increase of 6.11%, turnover rate of 6.57%, six-month line at 24.40 yuan, latest price at 25.54 yuan, and a divergence rate of 4.68% [1] - Dongbai Group (600693) with a price increase of 3.53%, turnover rate of 5.38%, six-month line at 6.27 yuan, latest price at 6.45 yuan, and a divergence rate of 2.88% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Tianbang Food (002124) with a price increase of 3.30%, turnover rate of 4.80%, six-month line at 3.05 yuan, latest price at 3.13 yuan, and a divergence rate of 2.74% [1] - *ST Haiyuan (002529) with a price increase of 5.06%, turnover rate of 1.38%, six-month line at 6.68 yuan, latest price at 6.85 yuan, and a divergence rate of 2.53% [1] - Senqilin (002984) with a price increase of 4.22%, turnover rate of 4.06%, six-month line at 20.00 yuan, latest price at 20.48 yuan, and a divergence rate of 2.43% [1]

Company Overview - Sichuang Medical Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on November 21, 2003. The company was listed on April 30, 2010. Its main business focuses on smart hospital solutions, including disease research management solutions, smart medical community solutions, healthcare service operations, and AI services based on big data [1][2]. Financial Performance - For the first half of 2025, Sichuang Medical achieved operating revenue of 545 million yuan, representing a year-on-year growth of 37.32%. However, the net profit attributable to the parent company was -51.83 million yuan, which is a year-on-year increase of 76.74% in losses [2]. - Since its A-share listing, the company has distributed a total of 532 million yuan in dividends, with no dividends distributed in the past three years [3]. Stock Performance - On August 26, the stock price of Sichuang Medical rose by 2.17%, reaching 3.77 yuan per share, with a trading volume of 84.04 million yuan and a turnover rate of 2.04%. The total market capitalization is 4.214 billion yuan [1]. - Year-to-date, the stock price has increased by 24.01%, with a 7.10% rise over the last five trading days, a 4.56% decline over the last 20 days, and a 2.17% increase over the last 60 days [1]. Shareholder Information - As of June 30, the number of shareholders of Sichuang Medical was 65,800, a decrease of 10.81% from the previous period. The average circulating shares per person increased by 12.11% to 16,914 shares [2]. Industry Classification - Sichuang Medical is classified under the Shenwan industry as part of the Computer-IT Services II-IT Services III sector. It is associated with concepts such as assisted reproduction, Healthy China, smart healthcare, family doctor concepts, and internet healthcare [2].

Core Viewpoint - The financial performance of Sichuang Medical (300078) shows significant revenue growth but also highlights challenges in profitability and cash flow management [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 reached 545 million yuan, a year-on-year increase of 37.32% compared to 397 million yuan in 2024 [1]. - The net profit attributable to shareholders was -51.83 million yuan, improving by 76.74% from -22.3 million yuan in the previous year [1]. - The gross profit margin decreased to 8.57%, down 44.26% from 15.38% in the previous year [1]. - The net profit margin improved to -9.85%, a significant increase of 82.68% from -56.86% in 2024 [1]. - The total of selling, administrative, and financial expenses was 86.6 million yuan, accounting for 15.89% of revenue, a decrease of 49.01% year-on-year [1]. Cash Flow and Debt Management - Cash and cash equivalents increased by 151.92% due to increased borrowings [3]. - The company reported a significant reduction in interest-bearing debt, down 68.91% to 339 million yuan [1]. - Operating cash flow showed a decline of 28.0%, attributed to increased tax payments related to property disposals [3]. Operational Insights - Accounts receivable accounted for 50.24% of total revenue, indicating a large volume of outstanding payments [1]. - The company disposed of investment properties, which significantly impacted both revenue and costs, with a revenue contribution of 293.46 million yuan from property disposals [3]. - Research and development expenses decreased by 50.99%, reflecting a reduction in R&D personnel in the medical sector [3]. Historical Performance Context - The company's historical return on invested capital (ROIC) has been weak, with a median of 4% over the past decade and a particularly poor ROIC of -32.19% in 2024 [4]. - The company has experienced four years of losses since its listing, indicating challenges in maintaining profitability [4].

Core Viewpoint - 思创医惠 reported its 2025 semi-annual report, highlighting a significant presence of institutional investors holding 14.15% of its total shares as of August 22, 2025 [1] Institutional Investors - A total of 7 institutional investors disclosed their holdings in 思创医惠, with a combined shareholding of 158 million shares [1] - The institutional ownership increased by 0.02 percentage points compared to the previous quarter [1] Public Funds - One new public fund disclosed its holdings this period, namely 汇添富中证互联网医疗指数(LOF)A [1] Foreign Investment - One foreign fund, BARCLAYS BANK PLC, increased its holdings by 0.40% compared to the previous period [1] - A new foreign institution, J.P.Morgan Securities PLC-自有资金, disclosed its holdings this period [1] - The foreign institutions that did not disclose their holdings this period include 高盛国际-自有资金 and MERRILL LYNCH INTERNATIONAL [1]

Core Viewpoint - The company announced the approval of a proposal to utilize part of its idle self-owned funds for cash management, with a total limit of up to 800 million RMB [1] Group 1 - The sixth board meeting is scheduled for August 21, 2025, where the cash management proposal will be reviewed [1] - The company and its subsidiaries will invest in high-security, high-liquidity, and low-risk financial products [1] - The usage period for the funds is valid for 12 months from the date of shareholder meeting approval, allowing for rolling use within the limit [1]